SPM
CRSP icon

Symmetry Peak Management’s CRISPR Therapeutics CRSP Stock Holding History

Symmetry Peak Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,500
Closed -$257K – 85
2020
Q2 		$257K Buy
+3,500
New +$205K 0.21% 62

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Symmetry Peak Management's CRSP Position: Q3 2020 in Review

Symmetry Peak Management sold out of CRISPR Therapeutics (CRSP) in Q3 2020, closing a stake of 3,500 shares — an estimated $257K sold.

Symmetry Peak Management first reported a position in CRSP in Q2 2020 and held it in 1 quarter. The position peaked at $257K in Q2 2020. 309 funds tracked by Wall St. Rank hold CRSP as of Q3 2020.

  • Symmetry Peak Management reported no remaining CRISPR Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Symmetry Peak Management sold 3,500 CRISPR Therapeutics shares in Q3 2020, an estimated $257K.
  • Symmetry Peak Management first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 1 quarter.
  • Symmetry Peak Management's CRISPR Therapeutics position peaked at $257K in Q2 2020.
  • 309 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2020.

Based on Symmetry Peak Management's 13F filing for Q3 2020, filed 16 Nov 2020.